+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Adjunctive therapy with eptifibatide administered as a double bolus plus infusion in a patient undergoing elective implantation of a coronary stent

Adjunctive therapy with eptifibatide administered as a double bolus plus infusion in a patient undergoing elective implantation of a coronary stent

Journal of Invasive Cardiology 12 Suppl D: 8d-9d

(PDF emailed within 1 workday: $29.90)

Accession: 045175567

Download citation: RISBibTeXText

PMID: 11156714

Related references

Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention. Journal of the American Heart Association 6(6), 2017

High-dose eptifibatide in elective coronary stent implantation Results of the ESPRIT trial. European Heart Journal 21(Abstract Supplement): 146, August-September, 2000

Clinical outcomes of intracoronary eptifibatide bolus only versus intracoronary bolus and intravenous infusion of eptifibatide in primary percutaneous coronary intervention. Acute Cardiac Care 14(1): 42-44, 2012

Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study. Journal of Pharmacy Practice 25(5): 537-540, 2013

Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation. Critical Pathways in Cardiology 11(4): 177-185, 2013

Extended-infusion eptifibatide to prevent stent thrombosis in a patient undergoing orthopedic surgery. Annals of PharmacoTherapy 45(5): E28-E28, 2011

Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention. Journal of Cardiovascular Medicine 12(1): 29-36, 2011

Comparison of outcomes between patients undergoing percutaneous coronary stent implantation with eptifibatide and abciximab: An analysis using propensity score methods. 2007

A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation 114(24): 2636-2643, 2006

Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenetics and Genomics 20(1): 18-25, 2010

Effect of a shortened-duration Eptifibatide infusion (75 mg) as adjunctive therapy for percutaneous coronary intervention on in-hospital cardiovascular outcomes and bleeding. American Journal of Cardiology 115(6): 707-710, 2015

Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. American Journal of Cardiology 87(11): 1293-1295, 2001

Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the coronary revascularization using integrilin and single bolus enoxaparin study. Journal of the American College of Cardiology 41(1): 20-25, January 1, 2003

Eptifibatide Bolus Dose During Elective Percutaneous Coronary Intervention. Cardiology Research 9(2): 107-110, 2018

The platelet-to-lymphocyte ratio as a predictor of all-cause mortality in patients with coronary artery disease undergoing elective percutaneous coronary intervention and stent implantation. Journal of the Saudi Heart Association 27(3): 144-151, 2015